Salubrinal

Cat. No.:	HY-15486
CAS No.:	405060-95-9
Molecular Formula:	$C_{21}H_{17}Cl_3N_4OS$
Molecular Weight:	479.8
Target:	Phosphatase; Autophagy; Apoptosis; HSV
Pathway:	Metabolic Enzyme/Protease; Autophagy; Apoptosis; Anti-infection
Storage:	4°C, protect from light * In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (104.21 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.0842 mL	10.4210 mL	20.8420 mL
	5 mM	0.4168 mL	2.0842 mL	4.1684 mL
	10 mM	0.2084 mL	1.0421 mL	2.0842 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 45% PEG300 >> 5% Tween-80 >> 50% saline
   Solubility: 10 mg/mL (20.84 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Salubrinal is a cell-permeable and selective inhibitor of eIF2α dephosphorylation[1]. Salubrinal acts as a dual-specificity phosphatase 2 (Dusp2) inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis[2]. Salubrinal has antiviral activity against HSV-1 and inhibits dephosphorylation of eIF2α mediated by the HSV-1 protein ICP34.5[3].

IC_{50} & Target		
	Dusp2	HSV-1

In Vitro

Salubrinal, a recently identified PP1 inhibitor capable to protect against endoplasmic reticulum (ER) stress in various model systems, strongly synergized with proteasome inhibitors to augment apoptotic death of different leukemic cell lines. Salubrinal preferentially seems to target the PP1/GADD34 complex, Salubrinal is of interest to examine whether the effect of Salubrinal could also be recapitulated by another inhibitor of this phosphatase. For this purpose cantharidin, wis selected, which is less toxic than okadaic acid, but which also blocks PP1 (IC_{50}=1.7 μM) activities[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Salubrinal is a synthetic chemical that inhibits de-phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2α).

Salubrinal significantly suppresses inflammation of the paws of CAIA mice. For instance, the clinical scores are 1.94±1.7 (placebo) and 0.31±0.6 (Salubrinal) on day 6; and 4.63±3.4 (placebo) and 1.09±1.6 (Salubrinal) on day 12. Consistent with the clinical scores, the thickening of the paws is also reduced in the Salubrinal-treated group. Furthermore, Salubrinal reduces the histological scores from 1.47±1.10 (N=16; placebo) to 0.59±0.64 (N=16; Salubrinal) (p=0.01)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Kinase Assay [1]

Phosphatase activities are determined on immunoprecipitates of the phosphatases. Briefly, 2×10^6 K562 cells are treated for 18 hr with Salubrinal (20 μM), PSI (10 nM), the combination of both drugs or okadaic acid (100 nM). After washing with PBS, cells are lysed for 15 min on ice either in PP1LB (for determination of PP1γ-activity; 20 mM Tris-HCl, pH 7.5, 1% Triton X-100, 10% glycerol, 132 mM NaCl, Roche complete protease inhibitor) or in RIPA (for PP2A), supplemented with Roche complete protease inhibitor). Cell lysates containing 500 μg (PP1γ) or 300 μg (PP2A) protein are immunoprecipitated overnight at 4°C with 2-3 μg of the appropriate antibodies and then incubated with Protein A-Sepharose. Immunoprecipitates are washed three times in lysis buffer, followed by resuspension in phosphatase assay buffer (PP2A: 20 mM Tris-HCl, pH7.5, 0.1 mM $CaCl_2$; PP1γ: 50 mM Tris HCl pH 7.0, 0.2 mM $MnCl_2$, 0.1 mM $CaCl_2$, 125 μg/mL BSA, 0.05% Tween 20), supplemented with 100 μM 6,8-difluoro-4-methyl-umbelliferyl phosphate (DiFMUP). Precipitates are allowed to react with substrate for 1 hr at 37°C on an Eppendorf Thermoshaker, centrifuged and DiFMU fluorescence is measured on a BioTek Lambda Fluoro 320 microplate reader (360 nm_{ex}/460 nm_{em}). Phosphatase activities are given as percent change relative to the control (DMSO treated cells) [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay [1]

Cellular viability is assessed by the WST-1 colorimetric assay. Assays are performed on 96 well plates with 2×10^4 K562 cells/well in triplicate with Salubrinal concentrations ranging from 5-75 μM (total volume of 200 μL, 18 hrs). Untreated cells served as negative control sample[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration [2]

Mice[2]

Using Balb/c female mice (~nine weeks old), CAIA is induced by intravenous injection of a 2 mg cocktail of ArthritoMAb antibodies on day 0 followed by intraperitoneal injection of 100 μg LPS on day 3. Mice are randomly divided into a placebo group and a Salubrinal-treated group. Salubrinal (2.0 mg/kg) is intravenously administered daily from day 0, while a solvent (49.5% PEG 400 and 0.5% Tween 80 in PBS) is administered to the placebo group.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nature. 2023 Sep;621(7977):188-195.
- Acta Biomater. 2020 Jun;109:229-243.
- Cell Prolif. 2021 Sep 28;e13133.
- EMBO Rep. 2022 Apr 11;e53932.
- Biomed Pharmacother. 2022 Dec 14;158:114133.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Drexler HC. Synergistic Apoptosis Induction in Leukemic Cells by the Phosphatase Inhibitor Salubrinal and Proteasome Inhibitors. PLoS One. 2009;4(1):e4161.

[2]. Hamamura K, et al. Salubrinal acts as a Dusp2 inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis. Cell Signal. 2015 Apr;27(4):828-35.

[3]. Bryant KF, et al. ICP34.5-dependent and -independent activities of salubrinal in herpes simplex virus-1 infected cells. Virology. 2008 Sep 30;379(2):197-204.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA